Interestingly, recent studies revealed that in chronic myelogenous leukemia (CML) SIRT1 inhibition can prevent the acquisition of mutations and may therefore represent a treatment to overcome drug resistance [52]. This evidence concerns the gene SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive.